Physician profile
Brooke Wolfe Gregory
NPI 1205474921
$1,630.36
in general payments reported to CMS, 2019-2025
28 companies · $19.35 in 2025
The $19.35 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $374 · 2022: $425 · 2023: $279 · 2024: $534 · 2025: $19.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $361.86 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Abbvie INC. | $229.64 | 2022-2024 | |
| Glaxosmithkline, LLC. | $138.04 | 2021-2023 | Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $87.08 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $83.37 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $77.45 | 2021-2024 | Airsupra |
| Exact Sciences Corporation | $57.10 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $54.35 | 2021-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.24 | 2024 | Trulance, Xifaxan |
| Axsome Therapeutics, INC. | $45.68 | 2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $40.41 | 2022-2023 | Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.12 | 2023-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $36.99 | 2024-2025 | Rexulti |
| Mylan Specialty L.P. | $36.70 | 2021-2023 | Yupelri |
| Hologic Sales and Service, LLC | $33.48 | 2024 | Aptima |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $30.05 | 2024 | Rexulti |
| Covis Pharma Gmbh | $29.02 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.97 | 2022 | |
| Merck Sharp & Dohme LLC | $26.83 | 2021 | |
| Pfizer INC. | $26.67 | 2021-2023 | |
| Dexcom, INC. | $24.02 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $15.60 | 2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $15.57 | 2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $15.07 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.77 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.88 | 2021 | |
| Genentech USA, INC. | $9.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.